Author | Age | Gender (%male) | Subject ethnicity | Severity of subject disease | Subject drug exposure documentation | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Subjects | Controls | Statistical test result | Subjects | Controls | Statistical test result | Index | Score | No. of groups | Sedatives | Antibiotics | Steroids | ||
Liu [30] | ? | ? | N | ? | ? | N | N | ? | ? | 1 | N | N | N |
Buttenschoen [41] | 56 (33 to 88) | N/A | N | 70 | N/A | N | N | ? | ? | n/a | N | N | N |
Pachot [31] | 68 (54 to 76) | 51 (42 to 65) | N | 62 | 52 | N | N | SAPS II | 51 (±5) | 2 | N | N | N |
West [32] | N/S | N/S | N | 42 | 100; 20; 56 | N | N | ? | ? | 2 | N | N | N |
Harter [33] | 48 ± 20 | 'Comparable’ | N | 71 | 12 | N | N | APACHE II | 13 ± 6 | 1 | N” | N | N |
Flohe [40] | 47 ± 18 | 37 ± 14 | N | 68 | 50 | N | N | ISS | 39 ± 9 | 1 | N | N | N |
Escoll [34] | 51 ± 12 | 49 ± 12 | N | ? | ? | N | N | ? | ? | 1 | N | N | N |
Heagy [39] | 49 ± 3; 44 ± 8 | ? | N | ? | ? | N | N | Mortality | 20%, 9.6% | 2 | N | N | N |
Calvano [35] | 60; 61 | 58 | N | 66; 66 | 66 | N | N | ? | ? | 2 | N | N | Yt |
Sfeir [36] | 63 ± 3 | 50 ± 7 | N* (p < 0.0001) | 80 | 50 | N | N | APACHE II | 27 ± 5 | 1 | N | N | N |
Kawasaki [42] | ? | N/A | N | ? | N/A | N | N | ASA | I to II | 1 | N | N | N |
Heagy [37] | 49 ± 21 | ? | N | 66 | ? | N | N | ? | ? | 4 | N | N | N |
Bergmann [38] | 60; 51 | 32 | N | ? | ? | N | N | MODS | 15 ± 1, 7 ± 1 | 2 | N | N | N |